Aktis OncologyAKTS +4.02%9 PS Ratio is 281.27 as of Jul. 08, 2026, which is 24% above its 10-year median of 227.69. GuruFocus rates AKTS with a GF Score™ of 9/100. Among 928 Biotechnology companies, Aktis Oncology ranks worse than 90.84% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aktis Oncology's share price is $28.69.
Aktis Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.10. Hence, Aktis Oncology's PS Ratio for today is 281.27.
The historical rank and industry rank for Aktis Oncology's PS Ratio or its related term are showing as below:
AKTS'
s PS Ratio Range Over the Past 10 Years
Min: 165.49 Med: 227.69 Max: 311.37
Current: 281.29
During the past 4 years, Aktis Oncology's highest PS Ratio was 311.37. The lowest was 165.49. And the median was 227.69.
AKTS's PS Ratio is ranked worse than 90.84% of 928
companies
in the Biotechnology industry
Industry Median: 9.59
vs AKTS: 281.29
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Aktis Oncology PS Ratio Related Terms
Aktis Oncology PS Ratio Historical Data
* Premium members only.
The historical data trend for Aktis Oncology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aktis Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aktis Oncology PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aktis Oncology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aktis Oncology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Aktis Oncology's Share Price of today is $28.69. Aktis Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Aktis Oncology (AKTS) has a PS Ratio of 281.27 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aktis Oncology and its competitors. This is 24% above median its historical median of 227.69. Over the past decade, Aktis Oncology's PS Ratio has ranged from 165.49 to 311.37. According to the industry distribution chart, Aktis Oncology ranks #843 out of 928 companies in the Biotechnology industry, placing it in the top 90.8%.
Is Aktis Oncology's PS Ratio too high?
Aktis Oncology's current PS Ratio of 281.27 is 24% above median its 10-year median of 227.69. Over the past 10 years, this metric has ranged from a low of 165.49 to a high of 311.37. The Biotechnology industry median PS Ratio is 9.59. Aktis Oncology's value of 281.27 is 2833% above this industry median. Based on the distribution chart, Aktis Oncology ranks #843 out of 928 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's PS Ratio compare to ZBIO and MLTX?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #843 out of 928 companies for PS Ratio. This places Aktis Oncology in the lower half of its industry. The industry median PS Ratio is 9.59. Aktis Oncology's value of 281.27 is 2833% above this benchmark. Historically, Aktis Oncology's own PS Ratio has ranged from 165.49 to 311.37 over the past decade. While the company's 10-year median is 227.69 vs. the industry median of 9.59, Aktis Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.59, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aktis Oncology's current PS Ratio of 281.27 is 2833% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aktis Oncology and its competitors. For the Biotechnology industry, the median PS Ratio is 9.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aktis Oncology's current PS Ratio is 281.27, which is 24% above median its own 10-year median of 227.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current PS Ratio of 281.27. The current PS Ratio is 281.27, which is 24% above median its 10-year median of 227.69 and 2833% above the Biotechnology industry median of 9.59. Aktis Oncology's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current PS Ratio is 281.27 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score
Get the complete analysis for AKTS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTS has been successfully added to your 